Capital flows, CMO moves, M&A. Eight editions a day, seven tiers, from the chopped neck.
ISABELLA'S ISLAYCapital MarketsOct 17, 8:03 AM EDT
GlobalFoundries has been selected to operate two new semiconductor manufacturing facilities in Malta, New York, funded by Japan under a landmark U.S.-Japan allied-nation investment initiative totaling up to $21 billion.
ReadingThis is not a facility deal. It is a shift in how semiconductor capacity gets financed and controlled. Allied nations now underwrite capacity; CFIUS approval becomes formality.
WatchIntel's second fab funding round. Whether the U.S. matches the Japan commitment dollar-for-dollar or revises its own semiconductor roadmap.
HENRI IVCapital MarketsOct 17, 8:03 AM EDT
LVMH and the broader European luxury sector shed €300 billion in market capitalization in 2026, driven by persistent weakness in China and organic contraction in fashion, leather goods, and cosmetics divisions.
ReadingLuxury allocation is now a duration bet on China's balance-sheet repair, not consumer appetite. Holding periods extend; entry windows narrow.
WatchQ4 2026 China comparable-store sales. If they flatten below -2%, the sector reprices lower by another 15-20%.
MACALLAN 1926Executive AppointmentsOct 17, 8:03 AM EDT
Better.com, the digital mortgage lender, appointed Linda Yaccarino, former CEO of X, to its board as the company navigates internal governance tensions and proxy-related pressures.
ReadingBoard appointments during proxy contests telegraph which faction is gaining leverage. Watch who else joins before the shareholder meeting.
WatchBetter.com's next governance announcement and proxy filing details. If two more names land before the vote, the incumbent slate is in trouble.
LOUIS XIIIVenture IntelligenceOct 17, 8:03 AM EDT
Indian Primary Market (Multiple IPOs)
· Zeebiz ↗India's primary market is set for a busy week with six mainboard IPOs scheduled to open for subscription between October 13 and October 19, 2026, including Fusion CX, Tonbo Imaging, Zetwerk, HD Fire Protect, and others.
ReadingIf these six price cleanly, India's IPO window stays open through Q4. If any struggles, the window tightens and 2027 becomes a refinance year.
WatchOversubscription ratios on Fusion CX and Zetwerk. Both are SaaS-adjacent. Weak demand signals capital rotation away from software.
PAPPY 23Capital MarketsOct 17, 8:03 AM EDT
David Tepper's Appaloosa Management has allocated 40% of its $7.7 billion portfolio to just three positions: Amazon, Micron Technology, and Taiwan Semiconductor Manufacturing Company, betting heavily on artificial intelligence infrastructure.
ReadingWhen allocators this large go this concentrated, it signals conviction on duration. Betting AI spend runs for 36+ months without major supply disruption.
WatchTepper's next 13F. If he adds to or trims any position, it signals whether AI capex acceleration is accelerating or merely holding.
JOHNNIE BLUEFinancial IntelligenceOct 17, 8:03 AM EDT
Credit Rating Agencies (Moody's, Fitch, S&P)
· IJR / MSN ↗Twenty-two state financial officers and Republican attorneys general are pressing the SEC and credit rating agencies to scrutinize alleged ESG methodology that they claim favors Chinese companies while downgrading U.S. businesses, particularly those in oil-friendly states.
ReadingESG as a credit-rating input is under formal scrutiny. Expect guidance revisions and potential methodology carve-outs for U.S. public entities within Q4 2026.
WatchThe SEC's formal response to the state AGs. If they open an investigation into rating agency practices, the entire ESG-as-credit-input framework gets revisited.
WELL POURVenture IntelligenceOct 17, 8:03 AM EDT
The U.S. IPO market for biotechs entered a holding pattern this week, with City Therapeutics and Iambic completing their offerings while no new major biotech IPOs are currently scheduled for the coming weeks.
ReadingBiotech IPO drought signals either pricing discipline or genuine uncertainty around public-market appetite. Watch for a Series D extension instead of a pop to the public markets.
WatchAny biotech raising Series D at post-2024 valuation levels. That becomes the proxy for when the IPO window reopens.
Leave catalogs to the libraries and archives. Join Brand101, the standard in brand identity → huanggoodman.com/brand-room